| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, ISO 9001, USP, BP |
| Suitable for: | Elderly, Children, Adult |
| State: | Solid |
| Purity: | >96% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
|
Product Name
|
High Quality Prasugrel CAS 150322-43-3 bulk Prasugrel Powder |
|
Appearance
|
white powder |
|
Assay
|
99%min, 98.0% --101.0% |
|
Test
|
HPLC
|
|
Certificate
|
ISO 9001
|
|
CAS
|
150322-43-3 |
| MF | C20H20FNO3S |
| Storage Temperature |
Cool Dry Place
|
Prasugrel (trade name Effient in the US and India, and Efient in the EU) is a pharmaceutical drug that acts as a platelet
inhibitor and is used to prevent thrombosis (blood clotting). It was developed by Daiichi Sankyo Co. and produced by Ube
and currently marketed in the United States in cooperation with Eli Lilly and Company.
Prasugrel was approved for use in Europe in February 2009, and in the US in July 2009, for the reduction of thrombotic
cardiovascular events (including stent thrombosis) in people with acute coronary syndrome (ACS) who are to be managed
with percutaneous coronary intervention (PCI).
Prasugrel is a new oral effective thienopyridine drug. Like clopidogrel, prasugrel is an inactive prodrug that is metabolically
converted to an active metabolite by the cytochrome P450 enzyme system to irreversibly inhibit P2Y12 adenosine diphosphate
receptors on platelets. Prasugrel is superior to clopidogrel, which explains why its pharmacokinetic properties are improved:
prasugrel has a higher conversion of pro-drugs to active metabolites and higher bioavailability, so it is more effective. Rapidly
and can reduce the difference in efficacy between individuals, to a greater extent reduce the incidence of major ischemic
cardiovascular events.
Company Information
Our Certificate
Our Service
Our Research
Packaging & Logistics
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}